Hong Sheng Xu

Amministratore Delegato presso Shapuaisi Qiangshen Pharma Co., Ltd.

42 anni

Health Technology

Profilo

Hong Sheng Xu is currently the General Manager & Director at Shapuaisi Qiangshen Pharma Co., Ltd.
Previously, he held the position of Chairman-Supervisory Board at Zhejiang Shapuaisi Pharmaceutical Co. Ltd.

Posizioni attive di Hong Sheng Xu

Società	Posizione	Inizio
Shapuaisi Qiangshen Pharma Co., Ltd. Shapuaisi Qiangshen Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Jilin Yueshi Tianbo Pharmaceutical Co., Ltd., Shapuaisi Qiangshen Pharma Co., Ltd. manufactures tablets, hard capsules, and granules. The company is based in Dongfeng County, China. The Chinese company was founded in 2014. The CEO is Hong Sheng Xu. Shapuaisi Qiangshen Pharma Co. was acquired by Jilin Yueshi Tianbo Pharmaceutical Co., Ltd. from Zhejiang Shapuaisi Pharmaceutical Co. Ltd. on January 26, 2022 for $12.50 million.	Amministratore Delegato	-

Tutte le posizioni attive di Hong Sheng Xu

Precedenti posizioni note di Hong Sheng Xu

Società	Posizione	Fine
ZHEJIANG SHAPUAISI PHARMACEUTICAL CO.,LTD.	Presidente	-

Vedi nel dettaglio l'esperienza di Hong Sheng Xu

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Hong Sheng Xu

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
ZHEJIANG SHAPUAISI PHARMACEUTICAL CO.,LTD.	Health Technology

Aziende private	1
Shapuaisi Qiangshen Pharma Co., Ltd. Shapuaisi Qiangshen Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Jilin Yueshi Tianbo Pharmaceutical Co., Ltd., Shapuaisi Qiangshen Pharma Co., Ltd. manufactures tablets, hard capsules, and granules. The company is based in Dongfeng County, China. The Chinese company was founded in 2014. The CEO is Hong Sheng Xu. Shapuaisi Qiangshen Pharma Co. was acquired by Jilin Yueshi Tianbo Pharmaceutical Co., Ltd. from Zhejiang Shapuaisi Pharmaceutical Co. Ltd. on January 26, 2022 for $12.50 million.	Health Technology